We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tumor Metastasis Promoters Identified

By Biotechdaily staff writers
Posted on 08 Jul 2002
Scientists seeking to explain why cancer tumors metastasize have found that a transcription protein known as NFAT (nuclear factor of activated T cells) is a target of signals from á6â4 integrin, which has been linked with several features of metastatic tumors, including epithelial cell motility, cellular survival, and carcinoma invasion. More...
The study was published June 24, 2002, in the on-line issue of Nature Cell Biology.

In order for a tumor to metastasize, certain genes have to be activated to produce enzymes necessary to invade blood vessel walls and penetrate other tissues. While looking for activators of these genes, researchers from Harvard Medical School (Boston, MA, USA) found high levels of NFAT in certain types of cancer cells.

Because there was no information indicating NFAT expression in human metastatic cancer, the researchers evaluated the presence of NFAT in tissue samples from five breast cancer patients with aggressive grade III ductal carcinoma, who had positive lymph node metastases at the time of diagnosis. Besides showing a high correlation between tumor aggression and NFAT levels, the researchers showed that NFAT is found in association with another protein, á6â4 integrin. This integrin has been linked with several traits of metastatic tumors, including epithelial cell motility, cellular survival, and carcinoma invasion.

"Cancer has been attacked from a large number of fronts, but this discovery presents a previously unappreciated role for NFAT in human cancer,” said Dr. Alex Toker, department of pathology at Harvard and senior author. "If we pursue this avenue and add NFAT to the growing list of proteins that have been shown to be important for disease progression, we could be offering a novel target for drug discovery to block this aspect of cancer progression. We may be providing another weapon in our arsenal in the fight against cancer.”

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Laboratory specialists and clinicians from 48 countries participated in this survey. Countries are indicated in red. (Omosule, Catherine L., Lang, Tim, Geaghan, Sharon M., et al. Mapping pediatric cardiac troponin testing worldwide: results from the IFCC survey on emerging applications, standardization needs and access. Chemistry and Laboratory Medicine (CCLM), 2026. https://doi.org/10.1515/cclm-2026-0711)

Global Survey Finds Pediatric Troponin Testing Lacks Consistent Reference Intervals

Cardiac troponin is released into the blood when heart muscle is damaged and is widely used as a rapid marker of cardiac injury in adults. In children, interpreting troponin results remains difficult because... Read more

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.